Barry Canton, identified in a recent Form 4 filed with the Securities and Exchange Commission, disposed of 26,271 shares of Ginkgo Bioworks Holdings, Inc. Class A Common Stock (NYSE: DNA) for an aggregate amount of approximately $175,067. The filing shows the sales took place on April 8 and April 9, 2026, with executed prices ranging from $6.397 to $6.93 per share.
The disclosure also notes that Canton acquired 55,476 shares of Class A Common Stock on April 7 and April 8, 2026, following the exercise of performance-based restricted stock units. The back-to-back timing of the exercise and subsequent sales is recorded in the same SEC filing.
At the time of reporting, DNA shares were trading around $6.45, a level representing a roughly 52% drop over the prior six months. Commentary from InvestingPro Tips included in the filing indicates the stock has experienced substantial declines and pronounced volatility during that period. The platform additionally characterizes DNA as undervalued according to its Fair Value analysis and notes that six further ProTips are available to subscribers.
Investors seeking deeper analysis can reference the Pro Research Report noted by the same service, which is available for DNA and more than 1,400 other U.S. equities on InvestingPro, according to the disclosure.
Separately, Ginkgo Bioworks reported fourth-quarter 2025 results that the company says show improved cash management and actions to restructure operations. The quarterly figures included a decline in revenue within the cell engineering segment. Nonetheless, aggressive cost-cutting initiatives apparently produced a marked reduction in operating losses and cash burn, as described in the earnings report.
Ginkgo also introduced the Ginkgo Cloud Lab, a web-based platform intended to give researchers remote access to the company’s automated laboratory systems. The new platform leverages what the company calls Reconfigurable Automation Carts, which combine robotic arms with maglev sample transport tracks to form a modular laboratory environment.
Following these strategic shifts, BTIG adjusted its outlook on the company, lowering its price target for Ginkgo Bioworks from $9.00 to $5.00 while retaining a Sell rating. The firm’s commentary cites the company’s emphasis on autonomous lab expansion as a factor in its reassessment. Ginkgo has stated plans to double the number of RAC cart automation systems in its Boston facility by the end of 2026.
These disclosures - the insider sales and exercises, the company’s operational restructuring and lab automation initiatives, and the broker re-rating - together paint a picture of active portfolio and strategic adjustments at Ginkgo Bioworks amid continued stock volatility.